<DOC>
	<DOC>NCT01349452</DOC>
	<brief_summary>Ganciclovir ophthalmic gel delivers multiple advantages in the treatment and prophylaxis of herpetic keratitis and shows potential for effectiveness against other viral ocular infections. The majority of adenoviral conjunctivitis will resolve without damaging vision, however, the investigators have no way to determine which cases will progress to ocular complications such as corneal infiltrates and pseudomembranes. Our purpose is to evaluate the efficacy of the Ganciclovir gel 0.15% in preventing ocular complications after adenoviral conjunctivitis.</brief_summary>
	<brief_title>Ganciclovir 0,15% Ophthalmic Gel in the Treatment of Adenovirus Keratoconjuntivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Adenoviridae Infections</mesh_term>
	<mesh_term>Conjunctivitis, Viral</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<mesh_term>Lubricant Eye Drops</mesh_term>
	<criteria>onset of symptoms for five days or less eighteen years old or more not pregnant or breastfeeding be able to understand and sign the consent term use of antibiotic or corticoid 30 days before monocular vision keratopathy or other ocular diseases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Conjunctivitis, Viral</keyword>
	<keyword>Adenoviridae Infections</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Adenovirus Keratoconjunctivitis</keyword>
	<keyword>Treatment of viral conjunctivitis</keyword>
</DOC>